Condition or disease | Intervention/treatment |
---|---|
Sepsis Septic Shock Critical Illness Respiratory Acidosis Respiratory Alkalosis Acid-Base Imbalance | Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma. Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood Diagnostic Test: Biomolecular analysis of plasma proteins. |
Acid-base equilibrium has been object of study for more than 100 years in medicine because of its relevance in patients' management and in determining their prognosis, especially in the ICU.
A concept closely related to acid-base equilibrium is that of "buffer", term used to define any substance able to limit the changes in pH caused by the addition or loss of alkali or acid.
Depending on its physiochemical features, every buffer has one or more pH (negative logarithm of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer dissolved in solution is half in its associated form (AH) and half in its dissociated form (A-).
Several studies tried to determine the normal values of both concentration and Ka of ATOT. However, they did not lead to univocal results. Moreover, many of these values come from studies of veterinary medicine or are the result of theoretical estimates on human plasma.
Staempfli and Constable performed a single experimental study on human plasma in 2003. These authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients with sepsis are still unknown.
Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of isolated plasma of critically ill patients with sepsis, and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).
Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that blood of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide).
Other aims of the study are:
Finally, possible structural alteration of plasma proteins will be evaluated:
Study Type : | Observational |
Estimated Enrollment : | 90 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Determination of Ka of Isolated Plasma and Whole Blood of Critically Ill Patients With Sepsis, Non-septic Patients and Healthy Volunteers: an International, In-vitro Acid-base Study. |
Actual Study Start Date : | June 3, 2019 |
Estimated Primary Completion Date : | June 2021 |
Estimated Study Completion Date : | June 2021 |
Group/Cohort | Intervention/treatment |
---|---|
Septic patients
Critically ill patients of both sexes admitted to the general ICU of the participating centers with the diagnosis of sepsis will be included.
|
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: Biomolecular analysis of plasma proteins. Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
|
Healthy controls
Age and sex matched healthy volunteers.
|
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: Biomolecular analysis of plasma proteins. Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
|
Non septic patients
Non-septic patients admitted to the general ICU of the participating centers after elective non-cardiac surgery.
|
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
Diagnostic Test: Biomolecular analysis of plasma proteins. Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Group 1: Septic patients
Inclusion Criteria for Group 1:
Exclusion Criteria for Group 1:
Group 2: Healthy volunteers
Inclusion criteria for Group 2:
Exclusion criteria for Group 2:
• Pregnancy
Group 3: Non-septic patients
Inclusion criteria for Group 3:
Exclusion criteria for Group 3:
Contact: Thomas Langer, MD | 0255033232 | thomas.langer@unimi.it |
Czechia | |
Third faculty of Medicine, Charles University of Prague | Recruiting |
Prague, Czechia | |
Contact: Frantisek Duska, MD fduska@yahoo.it | |
Principal Investigator: Frantisek Duska, MD | |
Sub-Investigator: Martin Krbec, MD | |
Sub-Investigator: Petr Waldauf, MD | |
Sub-Investigator: Tomas Urban, MD | |
Italy | |
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Recruiting |
Milan, Italy, 20122 | |
Contact: Thomas Langer, MD 025503 ext 3232 Thomas.Langer@unimi.it | |
Principal Investigator: Thomas Langer, MD | |
Sub-Investigator: Serena Brusatori, MD | |
Sub-Investigator: Annalisa Mauro, MD | |
Sub-Investigator: Paolo Brambilla, MD |
Principal Investigator: | Thomas Langer, MD | Fondazione IRCCS Ca' Granda Hospital, Milano, Italy | |
Study Chair: | Antonio M Pesenti, MD | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
Principal Investigator: | Frantisek Duska, MD | Third faculty of Medicine, Charles University, Prague | |
Study Chair: | Giacomo Grasselli, MD | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
Study Chair: | Paul Elbers, MD | Amsterdam UMC, Department of Intensive Care Medicine |
Tracking Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | May 27, 2019 | |||||||||||||||
First Posted Date | May 29, 2019 | |||||||||||||||
Last Update Posted Date | June 4, 2019 | |||||||||||||||
Actual Study Start Date | June 3, 2019 | |||||||||||||||
Estimated Primary Completion Date | June 2021 (Final data collection date for primary outcome measure) | |||||||||||||||
Current Primary Outcome Measures |
Effective dissociation constant of plasma weak acids (Ka) [dimensionless] [ Time Frame: 1 day ] Difference in plasma Ka between study groups.
|
|||||||||||||||
Original Primary Outcome Measures | Same as current | |||||||||||||||
Change History | ||||||||||||||||
Current Secondary Outcome Measures |
|
|||||||||||||||
Original Secondary Outcome Measures | Same as current | |||||||||||||||
Current Other Pre-specified Outcome Measures | Not Provided | |||||||||||||||
Original Other Pre-specified Outcome Measures | Not Provided | |||||||||||||||
Descriptive Information | ||||||||||||||||
Brief Title | Determination of the Dissociation Constant (Ka) of Plasma and Whole Blood in Septic Patients | |||||||||||||||
Official Title | Determination of Ka of Isolated Plasma and Whole Blood of Critically Ill Patients With Sepsis, Non-septic Patients and Healthy Volunteers: an International, In-vitro Acid-base Study. | |||||||||||||||
Brief Summary | Alterations of acid-base equilibrium are very common in critically ill patients and understanding their pathophysiology can be important to improve clinical treatment. | |||||||||||||||
Detailed Description |
Acid-base equilibrium has been object of study for more than 100 years in medicine because of its relevance in patients' management and in determining their prognosis, especially in the ICU. A concept closely related to acid-base equilibrium is that of "buffer", term used to define any substance able to limit the changes in pH caused by the addition or loss of alkali or acid. Depending on its physiochemical features, every buffer has one or more pH (negative logarithm of hydrogen ion concentration) values where its ability to keep pH stable is maximal. These values are defined as Ka or semi equivalence points, i.e. the pH values where the buffer dissolved in solution is half in its associated form (AH) and half in its dissociated form (A-). Several studies tried to determine the normal values of both concentration and Ka of ATOT. However, they did not lead to univocal results. Moreover, many of these values come from studies of veterinary medicine or are the result of theoretical estimates on human plasma. Staempfli and Constable performed a single experimental study on human plasma in 2003. These authors, however, analyzed only isolated plasma, neglecting whole blood, and computed ATOT and Ka values of healthy volunteers, while Ka and ATOT values for critically ill patients with sepsis are still unknown. Primary aim of the present study is to quantify the acidic dissociation constant (Ka) of isolated plasma of critically ill patients with sepsis, and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that plasma of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide). Secondary aim is to quantify the Ka of whole blood of critically ill patients with sepsis and compare these data with normal values, i.e. obtained from healthy controls. The investigators hypothesize that blood of critically ill septic patients has a lower Ka and that, consequently, it undergoes higher pH variations for a given perturbation of the system (variation in carbon dioxide). Other aims of the study are:
Finally, possible structural alteration of plasma proteins will be evaluated:
|
|||||||||||||||
Study Type | Observational | |||||||||||||||
Study Design | Observational Model: Case-Control Time Perspective: Prospective |
|||||||||||||||
Target Follow-Up Duration | Not Provided | |||||||||||||||
Biospecimen | Retention: Samples Without DNA Description:
Plasma samples in ethylenediaminetetraacetic acid for subsequent biomolecular analysis
|
|||||||||||||||
Sampling Method | Non-Probability Sample | |||||||||||||||
Study Population |
|
|||||||||||||||
Condition |
|
|||||||||||||||
Intervention |
|
|||||||||||||||
Study Groups/Cohorts |
|
|||||||||||||||
Publications * |
|
|||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||||||||
Recruitment Information | ||||||||||||||||
Recruitment Status | Unknown status | |||||||||||||||
Estimated Enrollment |
90 | |||||||||||||||
Original Estimated Enrollment | Same as current | |||||||||||||||
Estimated Study Completion Date | June 2021 | |||||||||||||||
Estimated Primary Completion Date | June 2021 (Final data collection date for primary outcome measure) | |||||||||||||||
Eligibility Criteria |
Group 1: Septic patients Inclusion Criteria for Group 1:
Exclusion Criteria for Group 1:
Group 2: Healthy volunteers Inclusion criteria for Group 2:
Exclusion criteria for Group 2: • Pregnancy Group 3: Non-septic patients Inclusion criteria for Group 3:
Exclusion criteria for Group 3:
|
|||||||||||||||
Sex/Gender |
|
|||||||||||||||
Ages | 18 Years and older (Adult, Older Adult) | |||||||||||||||
Accepts Healthy Volunteers | Yes | |||||||||||||||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||||||||||||||
Listed Location Countries | Czechia, Italy | |||||||||||||||
Removed Location Countries | ||||||||||||||||
Administrative Information | ||||||||||||||||
NCT Number | NCT03966664 | |||||||||||||||
Other Study ID Numbers | ENTERPRISE | |||||||||||||||
Has Data Monitoring Committee | No | |||||||||||||||
U.S. FDA-regulated Product |
|
|||||||||||||||
IPD Sharing Statement | Not Provided | |||||||||||||||
Responsible Party | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |||||||||||||||
Study Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |||||||||||||||
Collaborators | Charles University, Czech Republic | |||||||||||||||
Investigators |
|
|||||||||||||||
PRS Account | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |||||||||||||||
Verification Date | June 2019 |